Crossmark

Clinical response and pharmacokinetics of bendamustine as a component of salvage R-B(O)AD therapy for the treatment of primary central nervous system lymphoma (PCNSL)

Crossref DOI link: https://doi.org/10.1186/s12885-018-4632-y

Published Online: 2018-07-09

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kim, Therasa

Choi, He Yun

Lee, Hyun-Seo

Jung, Sung-Hoon

Ahn, Jae-Sook

Kim, Hyeoung-Joon

Lee, Je-Jung

Yoo, Hee-Doo

Yang, Deok-Hwan
Funding

Funding for this research was provided by:

Chonnam National University (KR) Hwasun Hospital (HCRI 16915-1)
License Information

Text and Data Mining valid from 2018-07-09
More Information

Article History

Received: 17 January 2018

Accepted: 25 June 2018

First Online: 9 July 2018

Ethics approval and consent to participate

: Study protocol was approved by the institutional ethics committee at Chonnam National University Hwasun Hospital (CNUHH-2016-145) and conducted in accordance to the Declaration of Helsinki principles. All patients provided written informed consent.

: Written informed consent for publication of clinical details, outcomes, and images was obtained from all patients. A copy of the consent form is available for review by the Editor of this journal.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below